Sign in

Steve Kregel, PhD

@stevekregel.bsky.social
315 followers 259 following 7 posts

Cancer Biologist studying prostate cancer at Loyola University Chicago. Kregellab.com

PostsRepliesMedia
Steve Kregel, PhD @stevekregel.bsky.social · 09/07/2026
New preprint from our group
000
Steve Kregel, PhD @stevekregel.bsky.social · 20/04/2026
#AACR26 @theaacr.bsky.social @aacrjournals.bsky.social
030
Reposted by Steve Kregel, PhD
AACR Journals @aacrjournals.bsky.social · 19/04/2026
Congratulations to Steven Kregel, PhD, and colleagues, recipients of the 2026 Molecular Cancer Research Award for Outstanding Journal Article! Read the article and learn more about this award: buff.ly/5xMOXPr #AACR26 @stevekregel.bsky.social
031
Reposted by Steve Kregel, PhD
Tim @timisstuck.bsky.social · 23/12/2025
Giving the gift of negative data 🥰 Since I joined @lsajournal.org I have handled several stellar manuscripts that report null results. These papers do very well and reviewers almost always appreciate them! Thanks @rockefeller.edu news team for the article! www.rockefeller.edu/news/38829-t...
rockefeller.edu
The value of publishing negative data - News
Scientific journals love news-worthy results. Editors want to publish studies with novel data that scientists will eagerly read and cite in their own work. Because of this desire for novelty, studies ...
27429
Reposted by Steve Kregel, PhD
bioRxiv Cancer Bio @biorxiv-cancer.bsky.social · 20/07/2025
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer www.biorxiv.org/content/10.1101/202…
031
Reposted by Steve Kregel, PhD
Daniel Gorelick @danielgorelick.bsky.social · 17/04/2025
Before WW2, UK led the world in many scientific domains, but its focus on centralized government laboratories rather than university partnerships stifled post-war commercialization. By contrast, USA channeled wartime research funds into universities www.nature.com/articles/d41...
nature.com
How the United States became a science superpower — and how quickly it could crumble
US global dominance in science was no accident, but a product of a far-seeing partnership between public and private sectors to boost innovation and economic growth.
042
Reposted by Steve Kregel, PhD
Denis Wirtz @deniswirtz.bsky.social · 27/03/2025
This is just horrible. The FY25 CR obliterates the already small funding allocations for the development of new treatments for patients with pancreatic cancer, lung cancer and glioblastoma.... for what purpose? These are three of the deadliest types of cancer.
36035
Steve Kregel, PhD @stevekregel.bsky.social · 18/01/2025
Proud to announce the publication of my master’s student Audris’s work on the pro-survival role of the linage specific, AR-cofactor NKX3.1 in prostate cancer cells! Take a look 👀 www.mdpi.com/2072-6694/17...
mdpi.com
The Homeobox Transcription Factor NKX3.1 Displays an Oncogenic Role in Castration-Resistant Prostate Cancer Cells
Background/Objectives: Prostate cancer (PCa) is the second leading cause of cancer-related death in men. The increase in incidence rates of more advanced and aggressive forms of the disease year-to-ye...
090
Steve Kregel, PhD @stevekregel.bsky.social · 19/12/2024
020
Reposted by Steve Kregel, PhD
Denis Wirtz @deniswirtz.bsky.social · 17/11/2024
Download our database of 492 (!) funding opportunities for EARLY-CAREER FACULTY AND RESEARCHERS. For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship). Download freely here: research.jhu.edu/rdt/funding-...
12558332
Steve Kregel, PhD @stevekregel.bsky.social · 16/11/2024
www.urotoday.com/categories-m...
urotoday.com
Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel
Andrea Miyahira hosts Steven Kregel to discuss a published paper on humanized mouse models for metastatic prostate cancer. Dr. Kregel discusses the challenges of modeling prostate cancer in mice and i...
030